KLK3 and prostate cancer: Brachytherapy boost could be considered for locally advanced disease to minimize the risk of PSA5 and local failure.26,27 A recently activated trial28 is now randomizing men with high-risk prostate cancer and persistently detectable PSA levels after EBRT and 6 to 12 months of ADT29 to continued ADT with or without abiraterone/prednisone and apalutamide.